Indaba Capital Announces Sale of AST Revolution to Bruker
Bruker (NASDAQ:BRKR) was upgraded by analysts at Rothschild Redb to a "strong-buy" rating.
Bruker (NASDAQ:BRKR) was given a new $60.00 price target on by analysts at Redburn Partners.
Bruker (NASDAQ:BRKR) is now covered by analysts at Rothschild & Co Redburn. They set a "buy" rating and a $60.00 price target on the stock.
Spatial Biology Market Analysis and Forecast, 2025-2035: Stellaromics, RareCyte, and 10x Genomics Drive Innovation and Funding Momentum [Yahoo! Finance]